References
- Oregon Health Authority. Oregon Administrative Rules. Chapter 333- Division 333. Psilocybin. 2022. https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102
- Siegel JS, Daily JE, Perry DA, et al. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry. 2023;80(1):77–83.
- Acker L. One of the creators of Oregon’s legal psychedelic mushroom program leaves advisory board. The Oregonian. 2022. https://www.oregonlive.com/news/2022/03/one-of-the-creators-of-oregons-legal-psychedelic-mushroom-program-leaves-advisory-board.html
- Horton DM, Morrison B, Schmidt J. Systematized review of psychotherapeutic components of Psilocybin-Assisted psychotherapy. Am J Psychother. 2021;74(4):140–149.
- Oregon Health Authority. Oregon Administrative Rules. Facilitator Scope of Practice, 333-333-5130. 2022. https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102
- Holze F, Becker AM, Kolaczynska KE, et al. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin Pharma Therapeutics. 2022. DOI:10.1002/cpt.2821
- Salas-Wright CP, Cano M, Hodges J, et al. Driving while under the influence of hallucinogens: prevalence, correlates, and risk profiles. Drug Alcohol Depend. 2021;228:109055.
- Nayak SM, Gukasyan N, Barrett FS, et al. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54(5):240–245.
- Sarparast A, Thomas K, Malcolm B, et al. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022;239(6):1945–1976.
- Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila). 2022;60(2):143–158.
- Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology. 2022;239(6):1881–1891.
- Leonard JB, Anderson B, Klein-Schwartz W. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol. 2018;32(12):1286–1294.
- Simonsson O, Goldberg SB, Chambers R, et al. Prevalence and associations of classic psychedelic-related seizures in a population based sample. Drug Alcohol Depend. 2022;239:109586.
- Smith WR, Appelbaum PS. Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology. 2022;216:109165.